Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 정성애 | * |
dc.date.accessioned | 2016-08-27T04:08:11Z | - |
dc.date.available | 2016-08-27T04:08:11Z | - |
dc.date.issued | 2015 | * |
dc.identifier.issn | 0036-5521 | * |
dc.identifier.issn | 1502-7708 | * |
dc.identifier.other | OAK-14587 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/217018 | - |
dc.description.abstract | Objective. Real-world epidemiological data on tuberculosis (TB) infection in patients with inflammatory bowel disease (IBD) receiving TNF-alpha inhibitors are scarce. We investigated the risks for and case characteristics of TB in a large cohort of IBD patients treated with TNF-alpha inhibitors in Korea, where TB is endemic. Materials and methods. We performed an observational study on all TB cases identified in a cohort of 873 IBD subjects treated with TNF-alpha inhibitors from January 2001 to December 2013. The standardized incidence ratio (SIR) of TB was calculated using data from the matched general population. Results. A total of 25 newly developed TB cases were identified in the cohort (pulmonary TB, 84% [21/25]; extrapulmonary TB, 16% [4/25]). The adjusted SIR of TB was 41.7 (95% confidence interval, 25.3-58.0), compared with that of the matched general population. Nineteen of the 25 patients (76%) developed TB within 2-62 months of initiation of TNF-alpha inhibitor treatment despite screening negative for latent TB infection (LTBI), whereas three patients with LTBI (12%, 3/25) developed TB 3 months after completion of chemoprophylaxis. The outcomes of TB treatment were mostly favorable, although one death from peritoneal TB was noted. The type of TNF-alpha inhibitor prescribed (infliximab) was a significant predictor of TB (p = 0.033). Conclusions. TNF-alpha inhibitor treatment strikingly increases the risk of TB infection in an IBD population from a TB endemic area. Continuous evaluation of the development of de novo TB infection in IBD patients subjected to long-term TNF inhibitor therapy is mandatory. | * |
dc.language | English | * |
dc.publisher | INFORMA HEALTHCARE | * |
dc.subject | inflammatory bowel disease | * |
dc.subject | latent tuberculosis infection | * |
dc.subject | tuberculosis | * |
dc.subject | tumor necrosis factor-alpha inhibitor | * |
dc.title | Risks for opportunistic tuberculosis infection in a cohort of 873 patients with inflammatory bowel disease receiving a tumor necrosis factor-alpha inhibitor | * |
dc.type | Article | * |
dc.relation.issue | 3 | * |
dc.relation.volume | 50 | * |
dc.relation.index | SCI | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 312 | * |
dc.relation.lastpage | 320 | * |
dc.relation.journaltitle | SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY | * |
dc.identifier.doi | 10.3109/00365521.2014.1000960 | * |
dc.identifier.wosid | WOS:000349399400008 | * |
dc.author.google | Byun, Ja Min | * |
dc.author.google | Lee, Chang Kyun | * |
dc.author.google | Rhee, Sang Youl | * |
dc.author.google | Kim, Hyo-Jong | * |
dc.author.google | Im, Jong Pil | * |
dc.author.google | Park, Dong Il | * |
dc.author.google | Eun, Chang Soo | * |
dc.author.google | Jung, Sung-Ae | * |
dc.author.google | Shin, Jeong Eun | * |
dc.author.google | Lee, Kang-Moon | * |
dc.author.google | Cheon, Jae Hee | * |
dc.contributor.scopusid | 정성애(7403676915) | * |
dc.date.modifydate | 20240415140437 | * |